GKOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Glaukos Corp (GKOS) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock shows strong technical indicators, positive analyst sentiment, and hedge fund interest, which outweigh the insider selling and lack of recent news catalysts. The long-term growth potential of the Epioxa product and favorable price target revisions support this conclusion.
The technical indicators for GKOS are bullish. The MACD histogram is positive and expanding, the RSI is neutral at 66.747, and the moving averages (SMA_5 > SMA_20 > SMA_200) confirm an upward trend. The stock is trading near its resistance level (R1: 130.859) but has room to grow toward R2: 133.828.
Analysts have consistently raised price targets, with the latest targets ranging from $140 to $170, citing strong growth potential for Epioxa and iDose.
Hedge funds have significantly increased their buying activity by 318.02% over the last quarter.
Bullish technical indicators and strong historical performance trends.
Insiders have increased their selling activity by 126.48% over the last month.
No recent news or congress trading data to act as a short-term catalyst.
Concerns over the potential impact of Local Coverage Determination (LCD) on iDose procedures, although analysts believe the downside is limited.
No financial data is available for the latest quarter, but previous analyst notes highlight strong Q1 results with revenue and forward guidance exceeding expectations, driven by the adoption of iDose and early traction of Epioxa.
Analysts maintain a strong buy consensus, with multiple firms raising price targets recently. Needham, Citi, and Goldman Sachs have all expressed optimism about Epioxa's growth potential and the company's ability to offset potential LCD impacts. The most recent price targets range from $140 to $170, reflecting confidence in the stock's upside.
